Jiangxi Rimag (HKG:2522) agreed to place 35 million new H shares at HK$16.76 apiece under its general mandate, raising net proceeds of about HK$562.1 million, according to a Friday Hong Kong bourse filing.

The placing shares represent about 13.6% of the company's existing issued H shares and 9.6% of the total issued share capital. On an enlarged basis, they account for about 11.9% of H shares and 8.8% of the total issued share base.

The placing price reflects a 12.5% discount to the last close and a 17.3% discount to the five-day average.

Proceeds will be used to strengthen AI and data service capabilities, expand medical imaging centers in China and overseas, invest in third-party healthcare enterprises, and for general working capital.